Anti-TRAF6 monoclonal antibody
Pre-made anti-TRAF6 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to TRAF6/TRAF6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T15051-Ab-1/ GM-Tg-hg-T15051-Ab-2 | Anti-Human TRAF6 monoclonal antibody | Human |
GM-Tg-rg-T15051-Ab-1/ GM-Tg-rg-T15051-Ab-2 | Anti-Rat TRAF6 monoclonal antibody | Rat |
GM-Tg-mg-T15051-Ab-1/ GM-Tg-mg-T15051-Ab-2 | Anti-Mouse TRAF6 monoclonal antibody | Mouse |
GM-Tg-cynog-T15051-Ab-1/ GM-Tg-cynog-T15051-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TRAF6 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T15051-Ab-1/ GM-Tg-felg-T15051-Ab-2 | Anti-Feline TRAF6 monoclonal antibody | Feline |
GM-Tg-cang-T15051-Ab-1/ GM-Tg-cang-T15051-Ab-2 | Anti-Canine TRAF6 monoclonal antibody | Canine |
GM-Tg-bovg-T15051-Ab-1/ GM-Tg-bovg-T15051-Ab-2 | Anti-Bovine TRAF6 monoclonal antibody | Bovine |
GM-Tg-equg-T15051-Ab-1/ GM-Tg-equg-T15051-Ab-2 | Anti-Equine TRAF6 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T15051-Ab-1/ GM-Tg-hg-T15051-Ab-2; GM-Tg-rg-T15051-Ab-1/ GM-Tg-rg-T15051-Ab-2; GM-Tg-mg-T15051-Ab-1/ GM-Tg-mg-T15051-Ab-2; GM-Tg-cynog-T15051-Ab-1/ GM-Tg-cynog-T15051-Ab-2; GM-Tg-felg-T15051-Ab-1/ GM-Tg-felg-T15051-Ab-2; GM-Tg-cang-T15051-Ab-1/ GM-Tg-cang-T15051-Ab-2; GM-Tg-bovg-T15051-Ab-1/ GM-Tg-bovg-T15051-Ab-2; GM-Tg-equg-T15051-Ab-1/ GM-Tg-equg-T15051-Ab-2 |
Products Name | Anti-TRAF6 monoclonal antibody |
Format | mab |
Target Name | TRAF6 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-TRAF6 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T15051-Ag-1 | Recombinant multi-species TRAF6/ MGC:3310/ RNF85 protein |
Cytokine | GM-Tg-g-T15051-Ag-1 | TNF receptor-associated factor 6, E3 ubiquitin protein ligase (TRAF6) protein |
ORF Viral Vector | pGMLP001351 | human NM_145803humanNM_145803 Lentivirus plasmid |
ORF Viral Vector | vGMLP001351 | human NM_145803humanNM_145803 Lentivirus particle |
ORF Viral Vector | pGMAD000221 | mouse Traf6 Adenovirus plasmid |
ORF Viral Vector | pGMLPm001259 | mouse Traf6 Lentivirus plasmid |
ORF Viral Vector | pGMLPm005412 | mouse Traf6 Lentivirus plasmid |
ORF Viral Vector | vGMAD000221 | mouse Traf6 Adenovirus particle |
ORF Viral Vector | vGMLPm001259 | mouse Traf6 Lentivirus particle |
ORF Viral Vector | vGMLPm005412 | mouse Traf6 Lentivirus particle |
Target information
Target ID | GM-T15051 |
Target Name | TRAF6 |
Gene ID | 7189,22034,311245,716907,100688110,101099750,539124,100052296 |
Gene Symbol and Synonyms | 2310003F17Rik,C630032O20Rik,MGC:3310,RNF85,TRAF6 |
Uniprot Accession | Q9Y4K3,B5DF45,B6CJY5,Q3ZCC3 |
Uniprot Entry Name | TRAF6_HUMAN,TRAF6_MACMU,TRAF6_RAT,TRAF6_BOVIN |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target, Cytokine Target |
Disease | Cancer |
Gene Ensembl | ENSG00000175104 |
Target Classification | Tumor-associated antigen (TAA) |
The target: TRAF6, gene name: TRAF6, also named as MGC:3310, RNF85. The protein encoded by this gene is a member of the TNF receptor associated factor (TRAF) protein family. TRAF proteins are associated with, and mediate signal transduction from, members of the TNF receptor superfamily. This protein has an amino terminal RING domain which is followed by four zinc-finger motifs, a central coiled-coil region and a highly conserved carboxyl terminal domain, known as the TRAF-C domain and mediates signaling from members of the TNF receptor superfamily as well as the Toll/IL-1 family. Signals from receptors such as CD40, TNFSF11/RANCE and IL-1 have been shown to be mediated by this protein. This protein also interacts with various protein kinases including IRAK1/IRAK, SRC and PKCzeta, which provides a link between distinct signaling pathways. This protein functions as a signal transducer in the NF-kappaB pathway that activates IkappaB kinase (IKK) in response to proinflammatory cytokines. The interaction of this protein with UBE2N/UBC13, and UBE2V1/UEV1A, which are ubiquitin conjugating enzymes catalyzing the formation of polyubiquitin chains, has been found to be required for IKK activation by this protein. This protein also interacts with the transforming growth factor (TGF) beta receptor complex and is required for Smad-independent activation of the JNK and p38 kinases. The protein encoded by this gene is a key molecule in antiviral innate and antigen-specific immune responses. [provided by RefSeq, Nov 2021].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.